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Introduction
The term mitochondrial medicine was first coined in 1994 by 
Luft, who 32 years earlier had described a patient suffering 
from hypermetabolism associated with profuse sweating and 
what were described as mitochondria defective in normal respi­
ratory control (Ernster et al., 1959; Luft et al., 1962; Luft, 1994). 
Luft syndrome was the first documented mitochondrial disease, 
and amazingly, the causative gene has still not been identified. 
As a relatively recent medical subspecialty, mitochondrial med­
icine is in its nascency. A major complication in patient diagno­
sis is that mutations in two genomes can result in mitochondrial 
disease, a factor that contributes to the panoply of associated 
phenotypes and varied timing for the onset of disease symptoms 
(Thorburn, 2004; Haas et al., 2008). Still, as 99% of proteins 
resident to mitochondria are encoded in the nuclear genome 
(Sickmann et al., 2003; Pagliarini et al., 2008), the majority of   
pediatric cases of mitochondrial disease exhibit typical Mende­
lian inheritance (Thorburn, 2004). Given the mitochondrion’s   
central role in ATP production, not surprisingly, oxidative   
phosphorylation  disorders  represent  a  major  class  of  mito­
chondrial disease (DiMauro and Schon, 2003; Thorburn et al., 
2004). In fact, current estimates indicate that 1 in 5,000 chil­
dren will develop an oxidative phosphorylation disorder, plac­
ing this disease category on par with lysosomal storage diseases 
as  the  most  prevalent  causes  of  inherited  metabolic  disease 
(Thorburn, 2004).
Of the 79 known nuclear mitochondrial disease–associated 
genes (Calvo et al., 2006; Calvo and Mootha, 2010), only   
one, TAZ1 (G4.5 or TAFAZZIN), the mutant gene associated 
with the X­linked disease Barth syndrome (BTHS; Online   
Mendelian Inheritance in Man [OMIM] accession no. 302060), 
is involved in the metabolism of the mitochondrial­specific phos­
pholipid cardiolipin (CL; Barth et al., 1983; Bione et al., 1996; 
Schlame and Ren, 2006). BTHS patients suffer from skeletal 
and cardiomyopathy and cyclic neutropenia. Heart failure and 
opportunistic infection are major causes of patient mortality, 
and  there  is  currently  no  documented  universal  therapeutic 
strategy. Mitochondria isolated from BTHS patients and models 
exhibit deficits in oxidative phosphorylation assembly and/or 
D
eficits  in  mitochondrial  function  result  in  many   
human diseases. The X-linked disease Barth syn-
drome (BTHS) is caused by mutations in the tafazzin 
gene TAZ1. Its product, Taz1p, participates in the metabo-
lism of cardiolipin, the signature phospholipid of mitochon-
dria. In this paper, a yeast BTHS mutant tafazzin panel is 
established, and 18 of the 21 tested BTHS missense muta-
tions  cannot  functionally  replace  endogenous  tafazzin. 
Four BTHS mutant tafazzins expressed at low levels are   
degraded by the intermembrane space AAA (i-AAA)   
protease,  suggesting  misfolding  of  the  mutant  poly-
peptides. Paradoxically, each of these mutant tafazzins   
assembles in normal protein complexes. Furthermore, in 
the absence of the i-AAA protease, increased expression 
and assembly of two of the BTHS mutants improve their 
function. However, the BTHS mutant complexes are ex-
tremely unstable and accumulate as insoluble aggregates 
when disassembled in the absence of the i-AAA protease. 
Thus, the loss of function for these BTHS mutants results from 
the inherent instability of the mutant tafazzin complexes.
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Saccharomyces cerevisiae Taz1p orthologue, resulted in two dis­
tinct biochemical fates: mislocalization to the mitochondrial matrix 
or altered assembly in macromolecular complexes (Claypool   
et al., 2006).
In the present study, we generate the complete collection 
of yeast BTHS mutant tafazzins by modeling the 21 missense 
mutations that occur at identical or conserved residues between 
the human and yeast orthologues. The power of the yeast model 
system to characterize the assorted BTHS mutant tafazzins is 
demonstrated by the fact that 18 of the 21 BTHS mutant ta­
fazzins fail to complement the taz1 yeast strain based on the 
accumulation of significant levels of the BTHS biomarker 
MLCL.  Our  further  in­depth  characterization  of  four  BTHS 
mutant tafazzins (four mutations at three loci) expressed at low 
levels demonstrates that each is degraded by the intermembrane 
space (IMS) AAA (i­AAA) protease quality control apparatus 
of the mitochondrial IM, suggesting misfolding of the mutant 
polypeptides. Paradoxically, each of these mutant tafazzins as­
sembles in normal protein complexes, arguing against a gross 
folding defect. Furthermore, in the absence of the i­AAA prote­
ase, the phospholipid profile of two of the BTHS mutants is   
improved, indicating recovered function. However, the BTHS 
mutant complexes are significantly more labile than wild­type (wt) 
Taz1p–containing complexes and, once disassembled, accumu­
late as insoluble protein aggregates in the absence of the i­AAA 
protease. Thus, we define a third mechanism explaining BTHS 
mutant tafazzin loss of function, tafazzin complex lability. To our 
knowledge, complex lability as a pathogenic mechanism has 
not been previously documented.
function (Barth et al., 1983, 1996; Ma et al., 2004; Brandner   
et al., 2005; McKenzie et al., 2006; Claypool et al., 2008b). CL, 
which is highly enriched in the mitochondrial inner membrane 
(IM), its site of synthesis, is an unusual dimeric phospholipid 
consisting of two phosphatidic acids bridged by a central glyc­
erol moiety (Schlame et al., 2000). The four typically saturated 
acyl chains of newly synthesized CL undergo a remodeling   
process, the end result of which is the incorporation of more un­
saturated fatty acyl chains that display a high degree of symme­
try (Schlame et al., 2005). Tafazzin (Taz1p), the gene product of 
TAZ1, is a key player in the remodeling of newly synthesized 
CL, functioning as a monolysocardiolipin (MLCL) transacylase 
(Xu et al., 2006). Remodeling is initiated by a phospholipase, 
which is identified in yeast as CL­specific deacylase 1 (Cld1; 
Beranek et al., 2009). In the absence of tafazzin activity, MLCL 
(only three acyl chains) accumulates, as the remodeling pathway   
is initiated but cannot be completed. Thus, MLCL is a biochem­
ical signature of BTHS (Valianpour et al., 2005; Houtkooper   
et al., 2009a).
Like many inherited disorders, there are a multitude of mu­
tations in TAZ1 associated with BTHS (Fig. 1). In addition to 
frameshift mutations that cause tafazzin truncation and mutations 
affecting splice donor and acceptor sites, 28 missense mutations 
have been documented. Based on the wide distribution of the   
missense mutations, it is reasonable to predict that there will 
be multiple mechanisms for the loss of function of BTHS 
mutant tafazzins. Support for this notion was provided by our 
previous demonstration that four BTHS mutations in a unique 
membrane anchor of Taz1p, when individually modeled in the 
Figure  1.  ClustalW  alignment  of  exon  5–deleted 
human  and  mouse  Taz1p  and  full-length  yeast 
Taz1p. BTHS mutations that occur at identical and 
conserved  amino  acids  are  indicated.  Truncation 
mutations  are  indicated  with  an  X  above  the  last 
amino acid translated in the mutant protein. Gray 
boxes highlight the conserved acyltransferase motifs 
A–E;  the  black  box  reveals  the  determined  loca-
tion of the integral interfacial membrane anchor of 
Taz1p. Asterisks indicate identical residues. Single 
dots indicate lesser conserved residues, and double 
dots indicate highly conserved residues.449 Pathogenic complex lability • Claypool et al.
Each of the identical and conserved BTHS missense mu­
tations was individually modeled in yeast tafazzin, generating a 
yeast BTHS mutant tafazzin panel (Fig. 2, highlighted in blue   
or red). Humanized yeast tafazzin constructs (Fig. 2, highlighted   
in green) were additionally generated for the BTHS mutations   
that occur at conserved residues to allow discrimination be­
tween a BTHS mutant–specific phenotype versus simple differ­
ences between the human and yeast polypeptides. The yeast 
BTHS mutant tafazzin panel was transformed into the taz1 
strain, and their expression was determined by immunoblotting 
(Fig. 2 A). Most of the mutant tafazzins were expressed at levels 
similar to wt Taz1p. However, some, including the previously 
characterized three membrane anchor mutants (V223D, V224R, 
and I226P), were expressed at drastically lower levels, even 
though all of the tafazzin variants are under control of the   
endogenous TAZ1 promoter. Next, the ability of each mutant ta­
fazzin to restore the altered phospholipid profile of the taz1 
strain was assessed. Critically, 18 of the 21 BTHS mutant tafazzins 
Results
Characterizing the yeast BTHS mutant 
tafazzin panel
The expression of human tafazzin is complicated by the pres­
ence of two potential start sites and alternative splicing (Bione 
et al., 1996; Houtkooper et al., 2009b). Of the multitude of de­
tected human Taz1p splice variants, only the exon 5–deleted 
isoform complemented a yeast strain lacking endogenous ta­
fazzin (taz1; Vaz et al., 2003). Consistent with this functional 
homology, a comparison of the amino acid sequences of exon 
5–deleted human and mouse Taz1p with the yeast orthologue 
revealed a substantial degree of conservation (18% identical 
and 41% conserved amino acids; Fig. 1). Furthermore, of the 
28 missense mutations currently documented in the BTHS   
patient population, 21 reside at either identical (Fig. 1, high­
lighted in red) or conserved (Fig. 1, highlighted in green) resi­
dues between the human and yeast orthologues.
Figure 2.  18/21 BTHS mutations result in dysfunctional yeast Taz1p. (A) The relative expression of each of the BTHS mutants was determined from whole-
cell extracts by immunoblotting for Taz1p (bottom) with -ketoglutarate dehydrogenase (KDH) serving as a loading control (top). (B) The relative abundance 
of MLCL was determined for each strain and is expressed as a percentage of the total phospholipid in each strain (means ± SEM; n = 3). The dashed red 
line indicates the highest level of MLCL detected in taz1 (WT Taz1). Asterisks indicate significant accumulations of MLCL relative to taz1 (WT Taz1;   
P < 0.001) as determined by one-way analysis of variance (ANOVA) with Holm–Sidak pairwise comparisons.JCB • VOLUME 192 • NUMBER 3 • 2011   450
Unlike most mitochondrial proteins, Taz1p lacks a typical   
N­terminal targeting signal. Thus, mutations within the tafazzin 
polypeptide could inactivate a cryptic internal mitochondrial 
localization  signal.  However,  each  of  the  four  mutant  ta­
fazzins cofractionated with mitochondria (Fig. 3 B) just like wt 
Taz1p. Thus, each BTHS mutant tafazzin retains normal mito­
chondrial targeting information. Yeast tafazzin normally associ­
ates with both the outer and inner mitochondrial membranes 
always facing the IMS (Claypool et al., 2006; Gebert et al., 
2009). Previously, we demonstrated that three BTHS mutations 
that  occur  in  the  unusual  membrane  anchor  of  yeast Taz1p 
(V223D, V224R, and I226P) result in their mislocalization to 
the mitochondrial matrix (Claypool et al., 2006). Importantly, 
each of these membrane anchor mutants is expressed at drasti­
cally reduced levels similar to the A88R/E, S140R, and L148H 
BTHS mutant tafazzins (Fig. 2 A). To determine whether the 
A88R/E, S140R, and/or L148H BTHS mutant tafazzin is mis­
localized within mitochondria, their submitochondrial localiza­
tion was ascertained by a proteinase K accessibility assay 
(Fig. 3 C). As with wt Taz1p, each of these BTHS mutant ta­
fazzins was degraded by added proteinase K upon disruption of 
the mitochondrial outer membrane (OM; mitoplast), demon­
strating that they are resident to IMS­facing membranes. In con­
trast, the V224R BTHS mutant tafazzin, which is mislocalized 
to the mitochondrial matrix, is only degraded by proteinase K 
upon the addition of the detergent Triton X­100 (TX­100). It is 
worth mentioning that CL­deficient mitochondria exhibit a 
failed to rescue the taz1 strain based on the significant mito­
chondrial accumulation of MLCL relative to taz1 yeast trans­
formed with wt Taz1p (Fig. 2 B). Importantly, with only one 
exception, humanized tafazzin constructs functioned as well as 
wt Taz1p. Furthermore, the humanized construct that failed to 
phenocopy wt Taz1p (N109D) did accumulate significantly less 
MLCL than the corresponding BTHS mutant (N109V). Inter­
estingly, greater variability was observed in the abundance of 
CL in the BTHS mutant tafazzin strains, with many containing 
significantly more CL than the empty vector–transformed taz1   
yeast strain (Fig. S1). From these analyses, clearly not every BTHS 
mutation is equivalent to a complete loss of function; otherwise, 
the MLCL and CL levels in each BTHS mutant strain would be 
expected to be the same as either the empty vector– or wt Taz1p–
transformed taz1 strain. Finally, these results validate using 
yeast to biochemically characterize each BTHS mutant tafazzin 
that fails to complement the taz1 yeast strain (18/21).
i-AAA protease–mediated degradation of 
four BTHS mutant tafazzins
To begin to characterize the BTHS mutant panel, we focused on 
four mutants occurring at three BTHS loci that were expressed 
at significantly lower levels than wt Taz1p: A88R/E, S140R, 
and L148H (Fig. 2 A, highlighted in red). Immunoprecipitation 
of Taz1p from [
35S]methionine/cysteine pulse­radiolabeled 
yeast  extracts  indicated  that,  as  expected,  all  four  mutant   
tafazzins are translated as robustly as wt Taz1p (Fig. 3 A).   
Figure 3.  The BTHS mutant tafazzins localize to and within mitochondria normally. (A) Immunoprecipitation (IP) of Taz1p from the indicated metaboli-
cally labeled yeast extracts. The asterisk highlights a nonspecific band. (B) Subcellular fractions were prepared from the indicated yeast strains through a 
series of differential centrifugations. 25 µg of each fraction was separated by SDS-PAGE and analyzed by immunoblotting using antisera specific for the 
indicated subcellular organelle. (C) Submitochondrial localization of wt and BTHS mutant tafazzins. Intact mitochondria, mitochondria subjected to osmotic 
shock (mitoplasts), or mitochondria solubilized with 0.1% TX-100 were incubated alone or in the presence of the indicated concentration of proteinase K. 
50 µg/lane wt Taz1p and 100 µg/lane BTHS mutants were resolved by SDS-PAGE and immunoblotted as indicated. For simplicity, only one set of control 
immunoblots is shown. The controls for every source of mitochondria are provided in Fig. S2. The four BTHS mutants being characterized in the present 
study are shown in red. The previously characterized matrix-mislocalized BTHS mutant tafazzin is shown in purple. KDH, -ketoglutarate dehydrogenase. 
Mito, mitochondria. (A–C) n = 3.451 Pathogenic complex lability • Claypool et al.
The expression of the four BTHS mutant tafazzins was com­
pared in taz1 strains harboring additional deletions of Oma1p 
(oma1; deletion monitored by PCR), the m­AAA protease 
(yta12;  deletion  confirmed  by  aberrant  processing  of  its 
substrate, cytochrome c peroxidase), or the i­AAA protease 
(yme1; Fig. 4 A). The expression level of wt Taz1p was invari­
ant in the absence of any of the three IM proteases. In contrast, 
the expression level of the A88R/E, S140R, and L148H BTHS 
mutant tafazzins was restored to wt levels in the absence of the 
major i­AAA protease subunit Yme1p. There was no impact on 
their expression in the absence of either Oma1p or the m­AAA 
protease. Yme1p is the major building block of the oligomeric 
i­AAA protease and is responsible for its proteolytic capacity. 
Recently, two additional subunits of the i­AAA protease, Mgr1p 
and Mgr3p, have been identified (Dunn et al., 2006, 2008). 
Consistent with the conclusion that Mgr1p and Mgr3p function 
as i­AAA protease adaptors that increase the efficiency of 
Yme1p­mediated proteolysis, the expression of the A88R/E, 
S140R, and L148H BTHS mutant tafazzins was partially re­
stored in the absence of either of these two proteins (Fig. 4 B). 
defective swelling response (Fig. S3; Ma et al., 2004); there­
fore, the failure to completely degrade Dld1p (positive control 
IMS protein) and the four BTHS mutant tafazzins upon mito­
plasting simply reflects an incomplete rupturing of the OM. 
Thus, the A88R/E, S140R, and L148H BTHS mutant tafazzins, 
all of which are expressed at steady state at extremely low levels, 
are translated as well as wt Taz1p and still localize to and within 
mitochondria normally.
Next, the possibility that each of these BTHS mutant ta­
fazzins was unable to fold subsequent to their proper sorting to 
and within mitochondria was addressed. The mitochondrial IM 
contains three resident proteases implicated in enforcing quality 
control in this compartment: Oma1p, the matrix AAA (m­AAA) 
protease, and the i­AAA protease (Tatsuta, 2009; Tatsuta and 
Langer, 2009). The m­AAA protease, in yeast composed of 
Yta10p  and Yta12p,  and  the  i­AAA  protease,  consisting  of 
Yme1p and the adaptor subunits Mgr1p and Mgr3p, are both 
embedded in the IM but have their active sites facing opposite 
sides. Oma1p has recently been demonstrated to degrade pre­
sumably misfolded Cox1p in coa2 yeast (Bestwick et al., 2010). 
Figure 4.  The BTHS mutant tafazzins are degraded by the i-AAA protease. (A and B) Steady-state expression was determined from whole-cell extracts 
derived from the indicated strains by immunoblotting for Taz1p, Yme1p, cytochrome c peroxidase (CCPO), and the loading control, porin. n = 3.   
(C) Increased half-life of the BTHS mutants in the absence of Yme1p. Whole-cell extracts were harvested after incubation with cycloheximide (CHX) for the 
indicated times, and the Taz1p remaining was determined by immunoblotting. Yme1p and porin are mitochondrial controls, and hexokinase (Hxk1p) is a 
cytosolic control. The four BTHS mutants being characterized in the present study are shown in red. Relative molecular masses are shown on the left.JCB • VOLUME 192 • NUMBER 3 • 2011   452
Collectively, these results indicate that the A88R/E, S140R, 
and L148H BTHS mutant tafazzins are targeted to and within 
mitochondria normally where they are rapidly degraded by the 
i­AAA protease. The simplest explanation for the rapid turn­
over of the four mutants is that they are unable to fold normally. 
However, when their assembly status was determined by 2D 
blue native (BN)/SDS­PAGE, each of the four BTHS mutant ta­
fazzins formed, with the exception of a single aberrant complex 
of 480 kD (Fig. 5 A, red arrows), the normal Taz1p complexes 
(Fig. 5 A). The assembly status of the four BTHS mutants was 
additionally assessed by glycerol density gradient centrifuga­
tion (Fig. 5 B). Consistent with the results of the 2D BN/SDS­
PAGE, the BTHS mutant tafazzins were detected in a range of 
complexes similar in size to those formed by wt Taz1p. Finally, as 
the formation of complexes presumes normal folding of a poly­
peptide, the ability of the four BTHS mutant tafazzins to associ­
ate with a known binding partner of yeast Taz1p, the major 
ADP/ATP carrier AAC2 (Claypool et al., 2008a), was directly 
assessed (Fig. 5 C). Indeed, each of the four BTHS mutant   
tafazzins  was  coimmunoprecipitated  with  endogenous AAC2. 
Next, in vivo degradation experiments were performed to deter­
mine the half­life of wt Taz1p and the four BTHS mutants, in 
the presence and absence of Yme1p, after the inhibition of 
new protein synthesis by the addition of cycloheximide (CHX; 
Fig. 4 C). Relative to wt Taz1p (t1/2 = 243 h), each of the four 
BTHS mutant tafazzins has a significantly shorter half­life   
(t1/2 of 4–6 h; Fig. 4 C). Although not restored to wt Taz1p values, 
the half­life of the A88R/E, S140R, and L148H BTHS mutant 
tafazzins was significantly increased in the absence of Yme1p. 
The increase in the half­lives of the four BTHS mutants in the 
absence of Yme1p is in contrast to the shorter half­life calcu­
lated for wt Taz1p in the absence of the i­AAA protease (t1/2 = 
158 h). One possible explanation for this observation is that 
perhaps Yme1p is involved in the routine quality control of 
Taz1p, and in its absence, more suboptimal Taz1p exists that is 
intrinsically less stable and capable of being degraded by pro­
teases in addition to Yme1p. Interestingly, compared with wt   
Taz1p (t1/2 = 243 h), another mitochondrial protein (porin, t1/2 = 
1,824 h), and a cytosolic protein (hexokinase [Hxk1p], t1/2 = 
360 h), Yme1p itself has a relatively short half­life (t1/2 = 27 h).
Figure 5.  The BTHS mutant tafazzins assemble in normal complexes. (A) 1.5% (wt/vol) digitonin extracts from mitochondria derived from the indicated 
strains were resolved by 2D BN/SDS-PAGE, and Taz1p complexes were detected by immunoblotting. 150 µg taz1 (WT Taz1) and 250 µg taz1 yeast 
transformed with empty vector or BTHS mutant tafazzin were analyzed. The red arrows highlight a complex only detected in mutant tafazzin extracts.   
(B) Digitonin extracts from mitochondria derived from the indicated strains were separated by glycerol density gradient centrifugation, and collected frac-
tions (1 = top and 20 = bottom) were immunoblotted for F1- (top) and Taz1p (bottom). 100% of each BTHS mutant fraction was analyzed versus 40% 
of taz1 (WT Taz1) fractions. The numbers above the arrowheads indicate the molecular weights of the high molecular weight standards (Stds). n = 3.   
(C) Endogenous AAC2 was immunoprecipitated from digitonin extracts from the indicated mitochondria. 0.5% of the starting material and final flow 
through versus 100% of the material remaining attached to the immunoprecipitation beads after washing were immunoblotted for the indicated mitochon-
drial proteins. exp, exposure. The four BTHS mutants being characterized in the present study are shown in red. (A and C) n = 5.453 Pathogenic complex lability • Claypool et al.
327 within the Walker A motif disrupts ATP binding. In the ab­
sence of ATP binding, both Yme1p proteolytic and chaperone­
like activities are lost (Leonhard et al., 1999). Interestingly, the 
expression level of Yme1
K327R and Yme1
E541Q was higher than 
wt Yme1p (each construct under control of the YME1 promoter), 
suggesting that Yme1p regulates its own expression (Fig. 6 A). 
The expression level of the four BTHS mutants was the same in 
taz1yme1 transformed with either Yme1
K327R or Yme1
E541Q 
as the empty vector control. Thus, a catalytically active Yme1p 
is required to degrade the A88R/E, S140R, and L148H BTHS 
mutant tafazzins.
Proteolysis is expected to occur subsequent to physical 
recognition. To test this, Yme1p was affinity purified by virtue 
of an appended C­terminal His6 tag from taz1yme1 strains 
expressing either the A88E BTHS mutant or wt Taz1p and wt 
Yme1p, Yme1
K327R, Yme1
E541Q, or the empty vector (Fig. 6 B). 
wt Yme1p  failed  to  copurify  either  the A88E  or  wt  Taz1p.   
In contrast, Yme1
K327R and Yme1
E541Q copurified a small amount 
of the A88E mutant polypeptide. Importantly, wt Taz1p and the 
controls Tim22p, Cyt1p, Cox5,6p, F1­, AAC2 (all resident to 
IM), and porin (OM) were not copurified with either Yme1
K327R 
or Yme1
E541Q. Consistent with the minor detected interaction, 
The relatively weak association between the A88R and S140R 
BTHS mutants and AAC2 compared with the A88E and L148H 
mutants could reflect a slightly lower expression level of the 
former and/or indicate that these two mutants are more severely 
impaired than the A88E and L148H mutants. Thus, the assem­
bly of the A88R/E, S140R, and L148H mutants as determined 
by both 2D BN/SDS­PAGE and glycerol density gradient cen­
trifugation reflects their ability to engage in normal inter­
actions, indicating that the BTHS mutant tafazzins are not, as 
predicted, absolutely unable to fold. If these four BTHS mutant 
tafazzins are not grossly misfolded, why are they being de­
graded by the i­AAA protease?
Reintroduction of wt Yme1p into the taz1yme1 strain 
restored the expression of the four BTHS mutant tafazzins to 
low levels (Fig. 6 A). This prompted us to probe the ability of 
two defined Yme1p mutants to regulate the expression of the 
A88R/E, S140R, and L148H mutant tafazzins. The i­AAA pro­
tease contributes to mitochondrial quality control through its 
proteolytic activity and via its ability to provide, in some cases, 
chaperone­like properties (Leonhard et al., 1999). Mutation   
of glutamate 541 within the catalytic domain renders Yme1p 
proteolytically dead (Leonhard et al., 1996). Mutation of lysine 
Figure 6.  i-AAA protease mutants bind the A88E BTHS mutant, but not wt, tafazzin. (A) Steady-state expression was determined from whole-cell extracts 
derived from taz1yme1 yeast transformed with the indicated Taz1p and Yme1p variants by immunoblotting for Taz1p, Yme1p, and the loading control, 
porin. (B) Digitonin extracts from mitochondria derived from the indicated strains were subjected to Ni
2+ nitrilotriacetic acid (NiNTA) chromatography. The 
indicated amount of total, TCA-precipitated flow through, and bound material was resolved by SDS-PAGE and immunoblotted as indicated. The asterisk 
highlights the cross-reaction with porin of the AAC2 antiserum. (C) Digitonin extracts from mitochondria derived from the indicated strains were resolved by 
2D BN/SDS-PAGE, and Taz1p complexes were detected by immunoblotting. 150 µg taz1yme1 yeast transformed with empty vector or Yme1 mutants 
and 250 µg taz1yme1 (Wt Yme1) were analyzed. The four BTHS mutants being characterized in the present study are shown in red. Stds, molecular 
weight standards. (A–C) n = 3.JCB • VOLUME 192 • NUMBER 3 • 2011   454
Do the BTHS mutants accumulate in a nonmitochondrial 
compartment in the absence of the i­AAA protease? Based on 
their continued cofractionation with mitochondria, the A88R/E, 
S140R, and L148H mutant tafazzins localize normally to mito­
chondria even in the absence of Yme1p (Fig. 8 A). Moreover, 
the assembly status of wt, A88R/E, S140R, and L148H tafazzins 
is unaffected by the absence of Yme1p (Fig. 8 B). The only dis­
cernable  difference  minus Yme1p  is  that  the  BTHS  mutant 
complexes are more abundant. Finally, focusing on the A88E 
and L148H BTHS mutant tafazzins that had recovered function 
in the absence of the i­AAA protease, wt, A88E, and L148H ta­
fazzins still associate with IMS­facing membranes in the ab­
sence of Yme1p (Fig. 8 C). Notably, the overall rupturing of the 
OM (tracked by a decrease in the IMS signal with the addition 
of proteinase K to mitoplasts) was consistently better for A88E 
and L148H mitochondria in the absence versus the presence of 
Yme1p, which is consistent with the restored function of both 
mutants in the absence of the i­AAA protease (Fig. 7).
As a routine component of 2D BN/SDS­PAGE, the solubili­
zation efficiency of every source of mitochondria is determined. 
Through these analyses, it was noticed that the solubilization 
efficiency of the mutant tafazzins was specifically impaired in the 
absence of Yme1p. Thus, to determine whether the mutant ta­
fazzins are prone to aggregation in the absence of Yme1p, a se­
quential detergent solubilization assay was performed (Fig. 8 D). 
there was no discernable difference in the assembly of the A88E 
BTHS mutant tafazzin in the absence or presence of Yme1p, 
functional or not functional (Fig. 6 C). The failure to copurify 
the A88E mutant with wt Yme1p implies that substrate binding 
by Yme1p is quickly followed by substrate degradation.
Absence of Yme1p restores activity of 
A88E and L148H BTHS mutant tafazzins
Although not expected given the fact that the A88R/E, S140R, 
and L148H BTHS mutants are degraded by the mitochondrial 
quality control executioner Yme1p, the fact that these mutants 
did assemble normally (Fig. 5, A and B) prompted us to deter­
mine whether their accumulation in the absence of Yme1p restored 
MLCL and/or CL levels to normal. Amazingly, there were both 
significant decreases in the abundance of MLCL (Fig. 7 A) and 
increases in the abundance of CL (Fig. 7 B) in strains express­
ing the A88E and L148H BTHS mutants in the absence versus 
the presence of Yme1p. These results suggest that, in the ab­
sence  of  i­AAA  protease–mediated  degradation,  for  two  of 
these four mutant tafazzins, increased steady­state abundance 
correlates with the recovery of Taz1p function. If this is true, the 
CL that accumulates should resemble mature remodeled CL. 
Indeed, the abundance of the most common mature forms of CL in 
wt Taz1p–expressing yeast is increased in A88E and L148H BTHS 
mutant strains in the absence of the i­AAA protease (Fig. 7 C).
Figure 7.  Increased function of the A88E and L148H BTHS mutants in the absence of the i-AAA protease. (A and B) The relative abundance of MLCL (A)   
and CL (B) was determined for each strain and is expressed as a percentage of the total phospholipid in each strain (means ± SEM; n = 5). Student t tests   
were performed for each construct as expressed in taz1 and taz1yme1 yeast strains with significant differences indicated. (C) Comparison of CL in 
taz1 and taz1yme1 yeast strains transformed as indicated. The mass content of each molecular form of CL (acyl chain composition indicated) was de-
termined by multidimensional mass spectrometric array analyses by comparison of the peak intensity of each individual ion to that of the internal standard   
(means ± SEM; n = 3). The four BTHS mutants being characterized in the present study are shown in red. m/z, mass to charge ratio.455 Pathogenic complex lability • Claypool et al.
levels are partially restored, both mutants additionally accumu­
late in presumably nonfunctional protein aggregates.
BTHS mutant tafazzin complex lability
Still unclear is why the mutant tafazzins are even targeted for   
i­AAA protease–mediated degradation. One possibility is that 
the four mutant tafazzins are not imported into mitochondria as 
efficiently as wt Taz1p. To test this, wt mitochondria were incu­
bated with 
35S­labeled wt, A88R/E, S140R, or L148H tafazzins 
and treated with trypsin to remove nonimported proteins, and 
the OM was disrupted by osmotic shock in the absence or pres­
ence of proteinase K to degrade proteins in the IMS (Fig. 9 A). 
In this assay, protein aggregates accumulate in the TX­100 in­
soluble fraction (P2). In the presence of a functional i­AAA 
protease, both the A88E and L148H BTHS mutant tafazzins, 
similar to wt Taz1p, were readily solubilized by digitonin. How­
ever, in the absence of Yme1p, a sizeable proportion of the 
A88E and L148H mutant tafazzins was resistant to solubiliza­
tion by digitonin (detected in P1). Further extraction with   
TX­100 demonstrated that these two BTHS mutants accumu­
lated in TX­100–resistant aggregates (P2). wt Taz1p was equally 
extracted by digitonin in the presence or absence of Yme1p. Thus, 
whereas in the absence of Yme1p the abundance of A88E and 
L148H mutant tafazzin complexes is increased and the MLCL/CL 
Figure 8.  Increased assembly, but with protein aggregation, of the A88E and L148H BTHS mutants in the absence of the i-AAA protease. (A) Fractions were 
prepared from the indicated yeast strains through a series of differential centrifugations. 25 µg of each fraction was separated by SDS-PAGE and analyzed 
by immunoblotting for the indicated subcellular organelle. (B) Digitonin extracts from mitochondria derived from the indicated strains were resolved by 2D 
BN/SDS-PAGE, and Taz1p complexes were detected by immunoblotting. The red arrows highlight a complex only detected in mutant tafazzin extracts.   
250 µg (taz1 transformed with [A88R], [A88E], [S140R], or [L148H]) and 150 µg (all the rest) were analyzed. Stds, molecular weight standards. (A and B) n = 3.   
(C) Mitochondria derived from the indicated strains were treated exactly as described in Fig. 3 C. 50 µg/lane of each sample was resolved by SDS- 
PAGE and immunoblotted as indicated. (D) Solubility of Taz1p in detergents. Mitochondria isolated from the indicated strains were solubilized with   
digitonin and separated into a supernatant (S1) and pellet (P1) by centrifugation. Nonextracted material (P1) was solubilized with TX-100 and fractionated 
into a supernatant (S2) and pellet (P2) by centrifugation. Fractions were resolved by SDS-PAGE and immunoblotted as indicated. The asterisk highlights the 
cross-reaction with porin of the AAC2 antiserum. The four BTHS mutants being characterized in the present study are shown in red. Mito, mitochondria. 
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the routine assessment of Taz1p biogenesis and either the folding/
assembly of Taz1p is intrinsically inefficient or that chaper­
ones required for Taz1p folding/assembly are saturated in the   
in vitro assay. Collectively, these results indicate that the A88R/
E, S140R, and L148H BTHS mutants are imported into mito­
chondria as well as wt Taz1p.
The results from the in vitro import experiments further 
imply that the A88R/E, S140R, and L148H BTHS mutant ta­
fazzins are recognized as defective by the i­AAA protease soon 
after their import into IMS­facing membranes. Perhaps the sub­
sequent folding and/or assembly of the mutant tafazzins is less 
efficient than wt Taz1p, and the stalled assembly intermediates 
are recognized and degraded by the i­AAA protease. In the   
absence of the i­AAA protease, some of the stalled assembly 
intermediates eventually mature into fully assembled Taz1p 
complexes. The detection of more abundant mutant Taz1p   
complexes in the absence of Yme1p is entirely consistent with 
this possibility. Unfortunately, conditions have not been defined 
as of yet that allow assembly of wt Taz1p into mature Taz1p 
With only one exception, each of the BTHS mutants was im­
ported into IMS­facing membranes to a similar extent as wt 
Taz1p. After a 20­min import, significantly less A88E mutant 
tafazzin was productively imported into wt mitochondria than 
wt Taz1p. However, compared with the steady increase in im­
port of wt Taz1p over time, the amount of each BTHS mutant 
imported had plateaued or even decreased by the final import 
time point, suggesting that the mutants were already being   
recognized and degraded by the i­AAA protease. Therefore,   
in vitro import reactions were also performed using yme1  
mitochondria (Fig. 9 B). Indeed, all four tested BTHS mutants 
were imported into yme1 mitochondria to a similar extent as 
wt Taz1p. Moreover, there was a steady increase in import into 
yme1 mitochondria for each of the BTHS mutants over time. 
Finally, the import of each of the four BTHS mutant tafazzins 
was significantly better in yme1 than wt mitochondria (Fig. 9 C). 
The improved import of wt Taz1p into yme1 mitochondria 
(approaching the level of significance by the final time point) 
also indicates that the i­AAA protease is intimately involved in 
Figure 9.  The A88R/E, S140R, and L148H BTHS mutants are recognized as defective by the i-AAA protease quickly after import. (A and B) In vitro import 
of 
35S-radiolabeled wt Taz1 or the BTHS mutant Taz1 precursor into wt (A) or yme1 (B) mitochondria. The nonimported precursor was removed with 
trypsin, mitochondria were reisolated, and the OM was ruptured by osmotic shock in the absence or presence of proteinase K (Prot. K). C, control (2.5% 
of precursor proteins + 100 µg mitochondria). The samples were resolved by SDS-PAGE, the bottom half of the gel was analyzed by phosphoimaging, 
and the top half was immunoblotted for markers of the OM (Tom70p), membranes facing the IMS (Dld1p), and the matrix (-ketoglutarate dehydrogenase 
[KDH]). The percentage of each precursor imported at each time point was determined after phosphoimaging. Significant differences were determined by 
one-way ANOVA with Holm–Sidak pairwise comparisons and are indicated. Relative molecular masses are shown on the left. (C) Comparison of import 
into wt versus yme1 mitochondria. Significant differences between the percentage of each precursor imported into wt versus yme1 mitochondria were 
determined at each time point by Student t tests, with significant differences indicated. The four BTHS mutants being characterized in the present study are 
shown in red. Values are means ± SEM (n = 5–7 for import into wt mitochondria, and n = 4 for import into yme1 mitochondria).457 Pathogenic complex lability • Claypool et al.
mutant–containing complexes. To test this hypothesis, mitochon­
dria were isolated from yeast strains expressing wt Taz1p or the 
A88E BTHS mutant, in the presence or absence of Yme1p, after 
incubation with CHX for 8 or 48 h. wt Taz1p was readily solu­
bilized by digitonin, regardless of the presence or absence of 
Yme1p, even when new protein synthesis was inhibited for 2 d 
(Fig. 10, A [lanes 7–15 and 25–33] and B). As expected, the ab­
solute abundance of the A88E BTHS mutant in the presence of 
Yme1p was significantly decreased after 8­h CHX incubation 
complexes in organello (unpublished data). Thus, the kinetics of 
import and assembly of the mutant tafazzins cannot be com­
pared with wt Taz1p at present.
Another  possible  explanation  as  to  why  the  A88R/E, 
S140R, and L148H BTHS mutant tafazzins are degraded by the 
i­AAA protease is that complexes containing the mutant tafazzins 
assemble but fall apart at significantly faster rates. Further­
more, perhaps the accumulation in TX­100–insoluble aggre­
gates is a consequence of the unregulated disassembly of BTHS 
Figure 10.  BTHS mutant tafazzin complexes are unstable, and the mutant polypeptide accumulates in aggregates. Mitochondria were harvested from 
the indicated strains after incubation with CHX for the indicated times. (A) Solubility of Taz1p in detergents was determined as described in Fig. 8 D. The 
asterisk highlights the cross-reaction with porin of the AAC2 antiserum. For Taz1p immunoblots, 50 µg (taz1 [A88E]) and 20 µg (all the rest) were ana-
lyzed. For immunoblots of control proteins (Tom70p, F1-/, and AAC2), 20 µg was analyzed. (B) Versadoc-captured images were quantified using the 
affiliated Quantity One software, and the percentage of Taz1p in TX-100–insoluble aggregates and the percentage of Taz1p solubilized by digitonin were 
determined (means ± SEM; n = 5). Significant differences were determined by one-way ANOVA with Holm–Sidak pairwise comparisons and are indicated. 
(C) Digitonin extracts from mitochondria derived from the indicated strains were resolved by 1D BN-PAGE, and immunoblotting was performed for Taz1p, 
the ATP synthase/complex V (F1-), and respiratory supercomplexes (Cox2p). The migrations of the Vdimer, Vmonomer, III2IV2, and III2IV supercomplexes are 
indicated where appropriate. 250 µg (taz1[A88E]) and 150 µg (all the rest) were analyzed. 25 µg mitochondrial protein was additionally resolved by 
SDS-PAGE and immunoblotted as indicated. n = 3. (D) wt Taz1p assembles with partner proteins (generically denoted A) into final Taz1p complexes that 
are very stable. In contrast, the characterized BTHS mutant tafazzins have a retarded rate of assembly into final Taz1p complexes that quickly disassemble. 
The i-AAA protease recognizes both the delayed rate of BTHS mutant Taz1p assembly and the unregulated disassembly of Taz1p complexes. In the absence 
of the i-AAA protease, disassembled BTHS Taz1 forms aggregates. The BTHS mutants being characterized in the present study are shown in red.JCB • VOLUME 192 • NUMBER 3 • 2011   458
S. cerevisiae model system to characterize pathogenic muta­
tions that cause human disease.
The  detailed  characterization  of  four  BTHS  mutations   
occurring at three loci uncovered a paradox. Whereas the A88R/E, 
S140R, and L148H BTHS mutants are degraded by an inte­
gral component of the mitochondrial quality control machin­
ery, the i­AAA protease, suggestive of a severe folding defect 
of the mutants, each of the BTHS mutant tafazzins assem­
bled in roughly normal Taz1p complexes, just of reduced 
abundance. Moreover, each BTHS mutant tafazzin retained the 
ability to associate with the ADP/ATP carrier. Yeast Taz1p asso­
ciates with the ATP synthase and the ADP/ATP carrier in dis­
crete complexes (Claypool et al., 2008a). Still, the composition 
of the majority of the Taz1p interactome remains a mystery. The 
ability to engage in a normal range of physical interactions is 
strong evidence that the BTHS mutants are in fact able to fold 
properly. In the absence of Yme1p, the major subunit of the   
i­AAA protease, more BTHS mutant tafazzin complexes are de­
tected. This strongly suggests that the mutant tafazzins exhibit a 
retarded rate of assembly into final Taz1p­containing complexes 
(Fig. 10 D). This interpretation is based on the rationale that, if 
a BTHS mutant tafazzin had an increased frequency of forming 
dead­end assembly intermediates independent of Yme1p, the 
absence of the i­AAA protease should simply increase the abun­
dance of such misassemblies. The fact that more BTHS mutant 
tafazzin complexes are detected in the absence of Yme1p argues 
that the mutants can fold and assemble normally; they just do so 
with a reduced efficiency. Based on the significantly increased 
in vitro import into mitochondria devoid of Yme1p, the folding 
and/or assembly of Taz1p is normally monitored by the i­AAA 
protease. Yme1p recognizes the presumed defect in the folding 
and/or assembly of the four BTHS mutant tafazzins and then 
quickly and actively proteolyzes the mutant polypeptides sub­
sequent to a physical association. Thus, the delayed folding and 
assembly and consequent degradation by Yme1p undoubtedly 
contribute to the overall loss of function associated with these 
particular BTHS mutant tafazzins.
Strikingly, complexes containing the A88E BTHS mu­
tant tafazzin fall apart much faster than wt Taz1p complexes   
(Fig. 10 D). Moreover, in the absence of i­AAA protease– 
mediated degradation, disassembled BTHS mutant tafazzin   
accumulates in TX­100–insoluble aggregates. Therefore, although 
these four BTHS mutant tafazzins undoubtedly display a re­
duced rate of complex formation, the inherent instability of the 
formed complexes ensures that they fail to perform their physio­
logical tasks. To our knowledge, complex lability has never 
been described as an underlying pathogenic mechanism for a 
disease­associated mutation.
Why are the mutant tafazzin complexes more labile? One 
possibility is that perhaps while retaining the ability to fold, 
these four BTHS mutant tafazzins do so more loosely. Mutations 
that  destabilize  but  not  completely  destroy  tafazzin  structures 
would be expected to both delay folding and complex assembly 
and weaken complexes that are formed during a loosening event 
of the mutant tafazzin. Furthermore, such destabilized mutants 
might be predicted to be detected during their folding and as­
sembly by mitochondrial chaperones and/or Taz1p assembly 
(Fig. 10 C, bottom, lanes 1 and 2). Similar to wt Taz1p, the 
A88E mutant tafazzin remaining after 8­h CHX incubation was 
readily solubilized by digitonin when a functional i­AAA pro­
tease was present (Fig. 10, A [lanes 1–6] and B). In contrast, 
whereas the steady­state abundance of the A88E BTHS mutant 
in the absence of Yme1p remained stable throughout the CHX 
chase (Fig. 10 C, bottom, lanes 6–8), the fraction of A88E   
mutant tafazzin solubilized by digitonin decreased significantly 
after new protein synthesis was halted for 48 h (Fig. 10, A [lanes 
16–24]  and  B).  Moreover,  in  the  absence  of Yme1p,  the   
abundance of the A88E BTHS mutant detectable in the TX­100–
insoluble  P2  fraction  steadily  and  significantly  increased 
throughout the CHX chase (Fig. 10, A and B). Similar to the 
solubilization  data,  wt  Taz1p  complexes  were  stable  in  the   
absence of new protein synthesis for up to 2 d regardless of   
the presence or absence of the i­AAA protease (Fig. 10 C, top, 
lanes 3–5 and 9–11; 2D BN/SDS­PAGE analyses are shown in 
Fig. S4). In the presence of Yme1p, after only an 8­h incubation   
with CHX, A88E BTHS mutant complexes, like the poly­
peptide, were virtually undetectable (Fig. 10 C, lanes 1 and 2). 
Strikingly, in mitochondria lacking Yme1p, inhibition of new 
protein synthesis for only 8 h significantly reduced A88E BTHS 
mutant tafazzin complexes compared with control mitochondria 
not incubated with CHX. After 2­d CHX incubation, in the   
absence of Yme1p, A88E BTHS mutant complexes were un­
detectable even though the A88E polypeptide remained stable 
throughout the CHX chase (Fig. 10 C, lanes 6–8, compare top 
BN­PAGE with bottom SDS­PAGE). In stark contrast to the 
A88E mutant tafazzin complexes in the absence of Yme1p, ad­
ditional protein complexes of the mitochondrial IM (ATP syn­
thase, respiratory supercomplexes, and AAC2 complexes) and 
OM (porin complexes) persisted even in the absence of new 
protein synthesis for 2 d (Fig. 10 C and Fig. S4). Thus, A88E 
BTHS mutant tafazzin complexes are specifically and selec­
tively much more transient than wt Taz1p complexes. More­
over, the increased lability of the mutant complexes when 
expressed in the absence of the i­AAA protease correlates di­
rectly with the accumulation of BTHS mutant polypeptide in 
TX­100–insoluble aggregates.
Discussion
Currently there are 28 known missense mutations in tafazzin 
associated with the X­linked disease BTHS. With the exception 
of our previous characterization of four mutations present in the 
membrane anchor of Taz1p (Claypool et al., 2006), an explana­
tion for the inability to properly function as an MLCL trans­
acylase had not been provided for any of the other 24 BTHS 
mutant tafazzins. Here, we generate a panel of BTHS mutant 
yeast strains, focusing on the 21 missense mutations that occur 
at conserved positions in the human and yeast orthologues. 
Critically, 18 of the 21 tested BTHS mutant yeast strains accu­
mulated significant quantities of the stalled CL­remodeling inter­
mediate and BTHS biomarker MLCL, providing yet another 
illustration of the conservation of many basic mitochondrial 
processes from humans to fungi. Thus, the BTHS mutant yeast 
panel serves as another superb example of the power of the   459 Pathogenic complex lability • Claypool et al.
one-step gene replacement strategy (Wach et al., 1994). The yme1His1.1 
(MATa, leu2, ura3, trp1, ade8, yme1::HISMX6) strain has been described 
previously (Hwang et al., 2007).
Molecular biology and recombinant protein expression
pRS425wt Taz1 containing 300 bp of a 5 untranslated region has been 
described previously (Claypool et al., 2006). The series of BTHS point   
mutations were generated by overlap extension (Ho et al., 1989) using   
pRS425wt Taz1 as a template. Each construct was subcloned into pRS425wt 
Taz1.  For  in  vitro  transcription/translation,  the  open  reading  frame  of 
Taz1p was subcloned into pSP64. The A88R/E, S140R, and L148H BTHS 
mutants  were  shuttled  from  pRS425-based  constructs  into  pSP64yTaz. 
Yme1, including 500 bp of a 5 untranslated region and a C-terminal 
His6 tag, was amplified by PCR using genomic DNA isolated from the 
GA74-6A yeast strain as a template. Yme1
K327R and Yme1
E541Q were gen-
erated by overlap extension. All Yme1 constructs were cloned into the 2-µm 
vector pRS424. To generate yeast Dld1p (d-lactate dehydrogenase) con-
taining an N-terminal His6 tag, the entire open reading frame was cloned 
into the pET28a vector (EMD) in frame and downstream of the His6 tag, 
and the thrombin cleavage site was provided by the vector. His6Dld1 was 
induced  in  BL21-CodonPlus(DE3)-RIL  Escherichia  coli  (Agilent  Technolo-
gies), and inclusion bodies were isolated from native protein extracts by 
centrifugation at 10,000 g for 20 min at 4°C. Inclusion bodies were solu-
bilized with 3 ml of inclusion body solubilization buffer (1.67% [wt/vol] 
sarkosyl, 0.1-mM EDTA, 10-mM DTT, 10-mM Tris-CL, pH 7.4, and 0.05% 
polyethylene glycol 3350) by vigorous vortexing, incubated on ice for 20 min, 
and diluted with 6 ml of 10-mM Tris-CL, pH 7.4, and the solubilized pro-
teins were recovered after centrifugation for 10 min at 12,000 g at 4°C. After 
dialysis against phosphate-buffered saline, His6Dld1 was purified under 
native conditions using Ni
2+-agarose (QIAGEN) as per the manufacturer’s 
instructions. The sequence of every construct was verified by sequencing.
Antibodies
Most of the antibodies used in this work were generated in the Schatz or 
Koehler  laboratories  and  have  been  described  previously  (Poyton  and 
Schatz, 1975; Djavadi-Ohaniance et al., 1978; Maccecchini et al., 1979; 
Daum et al., 1982; Ohashi et al., 1982; Riezman et al., 1983; Scherer   
et al., 1990; Glick et al., 1992; Horst et al., 1997; Koehler et al., 1998; 
Claypool et al., 2006, 2008b; Hwang et al., 2007). Antibodies were 
raised in rabbits using His6Dld1 as an antigen. Other antibodies used 
were mouse anti-Sec62p (gift from D. Meyers, University of California, Los 
Angeles, Los Angeles, CA), mouse anti-yAAC2 (clone 6H8; Panneels   
et al., 2003), and horseradish peroxidase–conjugated secondary anti-
bodies (Thermo Fisher Scientific).
Metabolic labeling and immunoprecipitation of Taz1p
Yeast were grown overnight at 30°C in synthetic complete (SC)–Leu me-
dium. Each culture was diluted 1:10 in SC-Leu and grown at 30°C for   
90 min to OD600s of 0.4–1.0. 2.5 OD600 units of cells were resuspended 
with  0.4  ml  of  fresh  SC-Leu  and  incubated  at  30°C  while  shaking  at   
200 rpm for 15 min. Proteins were labeled at 30°C for 10 min with 150 µCi 
(two experiments) or 500 µCi (one experiment) trans–
35S-label (MP Bio-
medicals). Labeling was terminated by transferring the cells to an equal 
volume of ice-cold 2× azide stop mix (20-mM NaN3, 40-mM cysteine,   
40-mM methionine, and 0.5 mg/ml BSA). Sedimented cells were washed 
with 0.5 ml of ice-cold distilled H2O, resuspended with 0.5 ml of 1%   
TX-100 (vol/vol) lysis buffer (20-mM Hepes-KOH, pH 7.4, 50-mM NaCl,   
1-mM EDTA, 2.5-mM MgCl2, and 0.1% SDS [wt/vol]) supplemented with 
protease inhibitors (1-mM PMSF, 10 µM leupeptin, 2 µM pepstatin A, and 
10 µM chymostatin), transferred to a microfuge tube containing 0.1 ml of 
glass beads, and disintegrated by vortexing on high for 30 min at 4°C. 
The lysate was transferred to a new tube, and the beads were washed with 
0.5 ml of 1% TX-100 (vol/vol) lysis buffer to recover all of the extract.   
Lysates were precleared twice (rotating at 4°C for 1 h/preclear) with normal 
rabbit serum (Lampire Biological Laboratories, Inc.) prebound to protein 
A–Sepharose (GE Healthcare). Tafazzin was captured from precleared   
lysates  with  rabbit  anti–yeast  tafazzin  antisera  prebound  to  protein   
A–Sepharose rotating at 4°C overnight. Immune complexes were sequentially 
washed (1 ml and 10-min rotating at 4°C/wash) twice with lysis buffer 
containing  0.1%  TX-100  (vol/vol),  twice  with  high  salt  wash  buffer 
(0.1% TX-100 [vol/vol], 20-mM Hepes-KOH, pH 7.4, and 500-mM NaCl), 
and once with low salt wash buffer (0.1% TX-100 [vol/vol] and 20-mM 
Hepes-KOH, pH 7.4). Bound material was resolved on 12% SDS-PAGE 
gels, and labeled proteins were detected using a K screen and an image 
scanner (Pharos FX Imager; Bio-Rad Laboratories).
factors, resulting in the degradation of the mutant polypeptides 
by the i­AAA protease. The dual observations that more mutant 
tafazzin complexes are detected in the absence of Yme1p but 
these complexes rapidly fall apart suggest that chaperones   
assisting in the folding and assembly of Taz1p are unable to   
efficiently promote the reassembly of mutant Taz1p complexes. 
Thus, for the four BTHS mutant tafazzins, the equilibrium be­
tween assembly and disassembly has been shifted significantly 
in the direction of disassembly. This strongly implies that the 
formation of stable Taz1p complexes is critical for normal   
tafazzin function. Therefore, the partial recovery in the MLCL 
and CL levels upon deletion of Yme1p was driven by the con­
tinual supply of newly translated A88E and L148H BTHS   
mutant tafazzins.
An obvious question is whether the results obtained with 
yeast accurately model the same mutations in human tafazzin as 
expressed either in patient samples or a mammalian model. Un­
fortunately, our efforts to raise antibodies against human Taz1p 
have yielded reagents that lack the required sensitivity and 
specificity to detect any of the endogenous tafazzin isoforms 
predicted at the mRNA level (Houtkooper et al., 2009b). This 
has significantly hampered the development of a mammalian 
cell culture model that is experimentally tractable and yet physio­
logically relevant. Similar to BTHS­derived cells, knockdown 
of tafazzin in HeLa cells results in a decrease in the abundance 
of CL (Gonzalvez et al., 2008). However, in contrast to BTHS­
derived cells, tafazzin knockdown HeLa cells did not signifi­
cantly accumulate MLCL, which is an established biomarker 
for  BTHS  (Houtkooper  et  al.,  2009a). The  Human Tafazzin 
(TAZ) Gene Mutation and Variation database available on the 
Barth Syndrome Foundation website is a wonderful resource 
that lists defined mutations, provides salient patient informa­
tion, and, when available, indicates whether decreased CL and/or   
increased MLCL was detected in a patient with a specific   
tafazzin lesion. Unfortunately, information regarding the CL 
and MLCL profiles in patients harboring G80R/E, G131R, and 
L139H tafazzin mutations, corresponding to the yeast A88R/E, 
S140R, and L148H BTHS mutants characterized in detail in the 
present study, are not currently available. The absence of this 
data likely reflects the fact that awareness of this serious human 
disease is incomplete at best and that an affordable and reliable 
method to detect CL and MLCL from blood spots has only re­
cently been established (Kulik et al., 2008). Thus, validation of 
the yeast BTHS mutant tafazzin library remains an important 
but challenging goal for our future investigations.
Materials and methods
Yeast strains
All strains were derived from the wt parental S. cerevisiae yeast strain 
GA74-1A (MATa, his3 –11,15, leu2, ura3, trp1, ade8, rho
+, mit
+). The   
taz1His1.5 (MATa, leu2, ura3, trp1, ade8, taz1::HISMX6) strain (Claypool   
et al., 2006) served as the parent for the BTHS tafazzin panel that con-
tained all of the IM proteases. To generate the taz1oma1 (MATa, leu2, 
trp1, ade8, taz1::URAMX, oma1::HISMX6), taz1yta12 (MATa, leu2, 
his3–11,15, ade8, taz1::URAMX, yta12::TRP), taz1yme1 (MATa, 
leu2, trp1, ade8, taz1::URAMX, yme1::HISMX6), taz1mgr1 (MATa, 
leu2,  trp1,  ade8,  taz1::URAMX,  mgr1::HISMX6),  and  taz1mgr3 
(MATa, leu2, trp1, ade8, taz1::URAMX, mgr3::HISMX6) strains, the entire 
open reading frame of each gene was replaced using the PCR-mediated   JCB • VOLUME 192 • NUMBER 3 • 2011   460
material (P2) was separated from solubilized extract (S2) by centrifugation 
for 10 min at 21,000 g at 4°C. The percentage of Taz1p in TX-100–insoluble 
aggregates and the percentage of Taz1p solubilized by digitonin were   
calculated as follows: P2/(S1 + S2 + P2) × 100 and S1/(S1 + S2 + P2) × 
100, in which S1, S2, and P2 are the volumes of Taz1p detected in frac-
tions S1, S2, and P2, respectively.
In organello import into mitochondria
Radiolabeled precursors were generated using an SP6 Quick Coupled 
Transcription/Translation system and guidelines (Promega) and a 
35S Easy-
Tag (PerkinElmer). Radiolabeled precursors were incubated for 5, 10, or 
20 min at 30°C with wt GA74-1A or yme1 mitochondria in import buffer 
(0.6-M  sorbitol,  2-mM  KH2PO4,  60-mM  KCl,  50-mM  Hepes,  10-mM 
MgCl2, 2.5-mM EDTA, pH 8.0, 5-mM l-methionine, 10 mg/ml BSA, 2-mM 
ADP, and 2-mM NADH). Import was stopped, and the nonimported precur-
sor was degraded with an equal volume of ice-cold BB7.4 (0.6-M sorbitol 
and 20-mM Hepes-KOH, pH 7.4) containing 40 µg/ml trypsin. Trypsin 
was inhibited with 100 µg/ml of soybean trypsin inhibitor, and mitochon-
dria were reisolated by spinning at 8,000 g for 5 min at 4°C. To rup-
ture the OM, mitoplasting was performed in the absence or presence of   
100 µg/ml proteinase K as previously described (Claypool et al., 2006). 
As  a  control,  the  wt  Taz1  precursor  was  incubated  with  mitochondria   
on ice for 20 min and treated with trypsin, or not treated, to remove a non-
imported precursor, and reisolated mitochondria were subjected to osmotic 
shock in the absence of proteinase K. This control demonstrates that import 
does not occur at 4°C and that trypsin removes all of the nonimported pre-
cursor. 100% of each time point and 2.5% of imported precursors were re-
solved on 12% SDS-PAGE gels and analyzed by phosphoimaging. The 
percentage of precursor imported was calculated as follows: (T/P) × 2.5, 
in which T is the volume of Taz1p at a given import time point, and P is the 
volume of the Taz1p precursor.
Miscellaneous
The performed experiments used mitochondria harvested from yeast grown 
at 30°C to an OD600 of 3 in synthetic lactateLeu (0.17% yeast nitrogen 
base minus amino acids and ammonium sulfate, 0.5% ammonium sulfate, 
0.2% Drop-out Mix Synthetic minus Leu, 0.05% dextrose, 2% lactic acid, 
3.4-mM CaCl2 2H2O, 8.5-mM NaCl, 2.95-mM MgCl2 6H2O, 7.35-mM 
KH2PO4, and 18.7-mM NH4Cl) in Figs. 3 (B and C), 5, 7 C, 8, 10, S2, 
and S4; rich lactate medium (1% yeast extract, 2% tryptone, 0.05% dex-
trose,  2%  lactic  acid,  3.4-mM  CaCl2  2H2O,  8.5-mM  NaCl,  2.95-mM 
MgCl2 6H2O, 7.35-mM KH2PO4, and 18.7-mM NH4Cl) in Figs. 9 and S3; 
and synthetic lactateLeu–His–Trp–Ura (0.17% yeast nitrogen base minus 
amino acids and ammonium sulfate, 0.5% ammonium sulfate, 0.2% Drop-
out Mix Synthetic minus Leu, His, Trp, and Ura, 0.05% dextrose, 2% lactic 
acid, 3.4-mM CaCl2 2H2O, 8.5-mM NaCl, 2.95-mM MgCl2 6H2O, 7.35-mM 
KH2PO4, and 18.7-mM NH4Cl) in Fig. 6 (B and C). The preparation of 
yeast cell extracts (SC media), subcellular fractionation, isolation of mito-
chondria, submitochondrial localization, 1D BN-PAGE, immunoblotting, 
and immunoblot quantitation were performed as previously described 
(Claypool et al., 2006); 2D BN/SDS-PAGE and AAC2 immunoprecipi-
tation (Claypool et al., 2008b) and phospholipid labeling (synthetic 
lactateLeu), extraction, and data collection (Claypool et al., 2006, 2008a) 
were  performed  as  previously  described.  Statistical  comparisons  were   
performed using SigmaPlot 11 software (Systat Software, Inc.).
Online supplemental material
Fig. S1 shows the CL levels in the BTHS mutant tafazzin panel. Fig. S2 
shows the submitochondrial localization of BTHS mutant tafazzins with 
additional controls. Fig. S3 shows the defective swelling response of   
CL-deficient mitochondria. Fig. S4 shows 2D BN/SDS-PAGE immuno-
blots  of  wt  and  A88E  tafazzin,  porin,  and  AAC2  in  the  presence  and   
absence  of  Yme1p  after  incubation  of  yeast  with  CHX.  Online  supple-
mental material is available at http://www.jcb.org/cgi/content/full/ 
jcb.201008177/DC1.
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In vivo degradation experiments
In vivo degradation experiments were performed essentially as described 
previously (Metzger et al., 2008). In brief, overnight cultures were resus-
pended to OD600 = 4.0 in SC media and incubated with shaking for 5 min 
at 30°C, and new protein synthesis was inhibited by the addition of CHX 
([200 µg/ml]final). At each time point, 0.5 ml of cells was transferred to a 
tube containing an equal volume of ice-cold 2× azide stop mix (20-mM 
NaN3 and 0.5 mg/ml BSA). Cells were pelleted by centrifugation (845 g 
for 10 min at 4°C), the supernatant was aspirated, and pellets were stored 
at 80°C until all time points were collected. The preparation of yeast cell 
extracts was performed otherwise as described previously (Claypool et al., 
2006). For quantitation of immunoblots, images captured with either a 
Versadoc (Bio-Rad Laboratories) or Fluorchem Q (Cell Biosciences, Inc.) 
quantitative digital imaging system were quantitated using Quantity One 
software (Bio-Rad Laboratories). Half-lives were determined from exponen-
tial curve fits using Excel (Microsoft). wt and BTHS mutant tafazzin half-lives 
were calculated using the mean of seven to eight individual repetitions. The 
half-life of Yme1p was calculated from experiments using taz1 (wt Taz1; 
n = 3). Data from the longer CHX chase studies were pooled together to 
calculate the half-life of porin (n = 42) and Hxk1p (n = 18).
Glycerol density gradient centrifugation
Glycerol density gradient centrifugation was performed essentially as de-
scribed previously (Tamura et al., 2009) with minor alterations. In brief,   
5  mg/ml  mitochondria  was  solubilized  with  lysis  buffer  base  (20-mM 
Hepes-KOH, pH 7.4, 50-mM NaCl, 0.1-mM EDTA, and 10% glycerol) 
supplemented with 1.5% (wt/vol) digitonin (Biosynth International, Inc.) 
and 1-mM PMSF for 30 min on ice; insoluble material was removed by 
centrifugation for 30 min at 21,000 g at 4°C. The 100-µl supernatant was 
placed onto a 5-ml glycerol step gradient (20–40%) in 20-mM Hepes-
KOH,  pH  7.4,  50-mM  NaCl,  50-mM  6-aminohexanoic  acid,  0.1-mM 
EDTA, and 0.1% (wt/vol) digitonin and then centrifuged at 45,000 rpm for 
15 h in a rotor (SW55Ti; Beckman Coulter) at 4°C. 270 µl of fractions was 
collected from the top. Proteins were precipitated with 20% TCA and then 
resolved by SDS-PAGE followed by immunoblotting.
Ni
2+ nitrilotriacetic acid purification
Detergent  solubilization  of  mitochondria  (5  mg/ml)  was  performed  for   
30 min on ice with lysis buffer base (20-mM Hepes-KOH, pH 7.4, 100-mM 
NaCl, 20-mM imidazole, 1-mM CaCl2, and 10% glycerol) supplemented 
with 1.5% (wt/vol) digitonin and protease inhibitors; insoluble material 
was removed by centrifugation for 30 min at 21,000 g at 4°C. 0.6 mg 
digitonin extract was added to a tube containing 25 µl Ni
2+ nitrilotriacetic 
acid beads (QIAGEN) and 0.88 ml lysis buffer base with added protease 
inhibitors and incubated by rotating at 4°C for 1 h. Nonbinding material 
was TCA precipitated. Beads were washed twice (1 ml and 10-min rotat-
ing at 4°C wash) with 0.1% digitonin wash buffer (20-mM Hepes-KOH,   
pH 7.4, 100-mM NaCl, 20-mM imidazole, 1-mM CaCl2, and 10% glyc-
erol), and bound material was eluted with sample buffer supplemented 
with 300-mM imidazole.
Multidimensional mass spectrometry–based shotgun lipidomic analysis of 
mitochondrial lipids
The yeast mitochondrial lipidome was determined using multidimensional 
mass spectrometry–based shotgun lipidomics as previously described (Han 
and Gross, 2005; Han et al., 2006; Yang et al., 2009). In brief, a 400-µg 
aliquot of mitochondrial protein was transferred to a disposable borosili-
cate glass tube. Internal standards as a premixture were added based on 
protein concentration. A modified Bligh and Dyer procedure was used to 
extract lipids from each mitochondrial preparation. Each lipid extract was re-
constituted with a volume of 200 µl/mg mitochondrial protein in chloroform/ 
methanol  (1:1;  vol/vol).  The  lipid  extracts  were  flushed  with  nitrogen, 
capped, and stored at 20°C for electrospray ionization mass spectro-
metric analysis.
Sequential solubilization assay
Protein aggregation was determined as previously described (Rabl et al., 
2009). In brief, mitochondria were solubilized with 1.5% (wt/vol) digitonin 
lysis buffer supplemented with protease inhibitors as previously described 
in the Ni
2+ nitrilotriacetic acid purification section. After centrifugation at 
4°C for 10 min at 21,000 g, solubilized material was transferred to a new 
tube, and nonsolubilized material (P1) was either directly analyzed or re-
solubilized for 30 min on ice with 1% (vol/vol) TX-100 lysis buffer (20-mM 
Hepes-KOH, pH 7.4, 20-mM imidazole, 10% glycerol, 100-mM NaCl, 
and 1-mM CaCl2) supplemented with protease inhibitors. TX-100–insoluble 461 Pathogenic complex lability • Claypool et al.
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